-
Mashup Score: 4
Background/Purpose: JAK inhibitors have been reported to be a promising treatment for dermatomyositis, an idiopathic inflammatory myopathy. However, the FDA recently added a black box label warning for all JAK inhibitors due to reports indicating increased risk of cardiovascular events, strokes, and cancer. Given these new safety concerns, this study leverages a large North American […]
Source: ACR Meeting AbstractsCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 2
Background/Purpose: JAK inhibitors have been reported to be a promising treatment for dermatomyositis, an idiopathic inflammatory myopathy. However, the FDA recently added a black box label warning for all JAK inhibitors due to reports indicating increased risk of cardiovascular events, strokes, and cancer. Given these new safety concerns, this study leverages a large North American […]
Source: ACR Meeting AbstractsCategories: Healthcare Professionals, Latest HeadlinesTweet-
Retrospective study looked at 47 adults w/ dermatomyositis treated with tofacitinib. While clinically similar, those on TOFA were were younger (53vs 61), shorter Rx duration (24 vs 53 mos);there was signif CDASI improvement. #ACR22 https://t.co/PEPmzZPeFr https://t.co/sS7IiYW9PR
-
-
Mashup Score: 7
Background/Purpose: JAK inhibitors have been reported to be a promising treatment for dermatomyositis, an idiopathic inflammatory myopathy. However, the FDA recently added a black box label warning for all JAK inhibitors due to reports indicating increased risk of cardiovascular events, strokes, and cancer. Given these new safety concerns, this study leverages a large North American […]
Source: ACR Meeting AbstractsCategories: Healthcare Professionals, Latest HeadlinesTweet-
Retrospective study looked at 47 adults w/ dermatomyositis treated with tofacitinib. While clinically similar, those on TOFA were were younger (53vs 61), shorter Rx duration (24 vs 53 mos);there was signif CDASI improvement. #ACR22 https://t.co/HrC1GLZQRR https://t.co/yiHsxhpiWe
-
-
Mashup Score: 3Characterization of Interstitial Lung Disease in the Presence of Antineutrophil Cytoplasmic Antibodies - ACR Meeting Abstracts - 1 year(s) ago
Background/Purpose: Various pulmonary manifestations may occur in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). ANCA-related interstitial lung disease (ILD) has recently been described in patients with or without overt AAV. The significance and evolution of this association remains unclear and has been raising research efforts in the past years. This study…
Source: ACR Meeting AbstractsCategories: Healthcare Professionals, Latest HeadlinesTweet-
Retrospective review of 265 ILD pts - 9.8% were ANCA positive (PR3, MPO). ANCA- oft called IPF. ANCA+ CTD-ILD and 65% evolved into AAV (29% AAV follwed ILD Dx). No lung diff betw Pos v Neg pts, but ANCA+ had more drugs, hosp. #ACR22 https://t.co/X6UfiawfmW https://t.co/BZpTsjYAFW
-
-
Mashup Score: 3Adult Onset Still's Disease: A Retrospective Study of Objective Manifestations and Outcomes - ACR Meeting Abstracts - 1 year(s) ago
Background/Purpose: Adult Onset Still’s Disease (AOSD) is a complex and rare inflammatory disease with life threatening complications. Due to its rarity and wide ranging clinical presentation, there is a lack of data regarding this patient population and their outcomes. Methods: We retrospectively identified hospitalized patients within the 185 hospital HCA database between 2016-2021 who were […]
Source: ACR Meeting AbstractsCategories: Healthcare Professionals, Latest HeadlinesTweet-
Retrospective review of 185 hospitalized AOSD pts (incidence 0.16 - 0.21/100K); Mean age 47 (70% female), mean ESR 55, CRP 12.26, ferritin 7141 WBC 12.15, anemia 23%. 24% ICU care & overall mortality was 3.2%. Ab#0829 #ACR22 https://t.co/eDRY4b3GAg https://t.co/3pt0ZH5QQH
-
-
Mashup Score: 0
Background/Purpose: The tools to assess disease activity and quality of life in axial spondyloarthritis (axSpA) were developed in ankylosing spondylitis cohorts biased towards inclusion of males. At present, it remains unclear how these tools capture disease experience in females. The Ankylosing Spondylitis Registry of Ireland (ASRI) is an epidemiological data source on patients with axSpA […]
Source: ACR Meeting AbstractsCategories: Healthcare Professionals, Latest HeadlinesTweet-
Do Disease Activity Measures Really Capture AS in Women? Dr. Rachel Tate ( @uptoTate) interviews Dr. Sinead Mcguire about Abstract 0406, presented at #ACR22 Convergence. Abstract 0406: https://t.co/u3HPrFnR8D… https://t.co/FlZojpb2Pz https://t.co/dm2aQwYh30
-
-
Mashup Score: 9
Background/Purpose: JAK inhibitors have been reported to be a promising treatment for dermatomyositis, an idiopathic inflammatory myopathy. However, the FDA recently added a black box label warning for all JAK inhibitors due to reports indicating increased risk of cardiovascular events, strokes, and cancer. Given these new safety concerns, this study leverages a large North American […]
Source: ACR Meeting AbstractsCategories: Healthcare Professionals, Latest HeadlinesTweet-
RT @uptoTate: Tofa may be option for pts w/ refractory skin predominant dermatomyositis. Abs 1887 #ACR22 @RheumNow https://t.co/heJ1kZeuPT…
-
-
Mashup Score: 2Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab: A Randomized Placebo-Controlled Trial - ACR Meeting Abstracts - 1 year(s) ago
Background/Purpose: Recent RCTs demonstrated that TNFα inhibition has no effect on pain and MRI-detected synovitis or bone marrow lesions in patients with erosive hand OA. However, the progression of bone erosions was reduced in a subgroup of patients with more clinically swollen distal interphalangeal joints in one RCT. Consequently, it remains possible that TNFα inhibition […]
Source: ACR Meeting AbstractsCategories: Latest Headlines, RheumatologyTweet-
RT @RichardPAConway: Maksymowych et al. RCT ofAdalimumab for knee OA!? it doesn't work. @RheumNow #ACR22 Abstr#1891 https://t.co/pfPVJ9A1Ex…
-
-
Mashup Score: 2Combined Biological or Targeted Therapy in Spondyloarthritis: Experience from a Multicenter Case Series in Spain - ACR Meeting Abstracts - 1 year(s) ago
Background/Purpose: Combined biological or targeted therapy (CBTT) is rarely considered in clinical practice due to contraindication in guidelines, potential safety concerns and high costs. However, previous successful experiences in inflammatory bowel disease (IBD) and our own early data in selected refractory spondyloarthritis (SpA) have shown encouraging results1. Our aim was to explore…
Source: ACR Meeting AbstractsCategories: Healthcare Professionals, Latest HeadlinesTweet-
RT @RichardPAConway: Valero et al. Combined biologics in PsA. @RheumNow #ACR22 Abstr1044 https://t.co/7nNf0Ktf0M https://t.co/CIE9BnBFvx
-
-
Mashup Score: 7From Practical Tips to Heartfelt Encouragement: How Social Media Can Improve Quality of Life with Rheumatic Disease - ACR Meeting Abstracts - 1 year(s) ago
Background/Purpose: Living with different autoimmune rheumatic diseases, we (Cheryl and Zoe) share similar struggles with disease management, and successes in learning new ways to use social media to support others and to cope ourselves in our disease journey. Cheryl was diagnosed with rheumatoid arthritis in 2003 at age 20. Today she is on her fourth […]
Source: ACR Meeting AbstractsCategories: Latest Headlines, RheumatologyTweet-
RT @CreakyJoints: Check out @realcc and @zoerothblatt #ACR22 patient perspective poster here: https://t.co/uXeaLDLiDi
-
Retrospective study looked at 47 adults w/ dermatomyositis treated with tofacitinib. While clinically similar, those on TOFA were were younger (53vs 61), shorter Rx duration (24 vs 53 mos);there was signif CDASI improvement. #ACR22 https://t.co/nZ8NgS4cZb